Your browser doesn't support javascript.
loading
CRISPR/Cas9 and AAV mediated insertion of ß2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy.
Meshitsuka, Sohsuke; Ninomiya, Ryo; Nagamura-Inoue, Tokiko; Okada, Takashi; Futami, Muneyoshi; Tojo, Arinobu.
Affiliation
  • Meshitsuka S; Department of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
  • Ninomiya R; Keijinkai Medical Corporation, Tokyo 160-0008, Japan.
  • Nagamura-Inoue T; Department of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
  • Okada T; Daiwa Pharmaceutical Co, Ltd., Tokyo 154-0024, Japan.
  • Futami M; Department of Cell Processing and Transfusion/Laboratory Medicine, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
  • Tojo A; Division of Molecular and Medical Genetics, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Regen Ther ; 21: 442-452, 2022 Dec.
Article in En | MEDLINE | ID: mdl-36313397
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Regen Ther Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Regen Ther Year: 2022 Document type: Article Affiliation country: Country of publication: